Servier completes the acquisition of Day One Biopharmaceuticals
Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?
Day One Biopharmaceuticals (NASDAQ:DAWN) Sets New 1-Year High – What’s Next?
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
Here Are Wednesday’s Top Wall Street Analyst Research Calls: CrowdStrike, Harley-Davidson, Intuitive Surgical, Medline, Nike, Oracle, Planet Fitness, Vici Properties, and More
Day One Biopharmaceuticals Touts OJEMDA Sales Surge, Sets $225M-$250M 2026 Outlook at TD Cowen
Here Are Tuesday’s Top Wall Street Analyst Research Calls: AT&T, Amgen, CrowdStrike, Gilead, Hims & Hers, Intuit, Lowe’s, Qualcomm, Rivian, Strategy and More
Are DAWN and TALK Obtaining Fair Deals for their Shareholders?
DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier
Day One Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Day One Biopharmaceuticals, Inc. - DAWN
Stock Market Today, March 6: Energy Stocks Rise as Oil Closes Over $90 on Middle East Tensions
SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Day One Biopharmaceuticals, Inc. (DAWN)
Shareholder Alert: The Ademi Firm investigates whether Day One Biopharmaceuticals, Inc. is obtaining a Fair Price for its Public Shareholders
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Day One Biopharmaceuticals, Inc. (NASDAQ: DAWN)
DAWN Stock Alert: Halper Sadeh LLC is Investigating Whether Day One Biopharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders
Day One Shares Surge After $2.5B Servier Deal
Servier to buy Day One Biopharmaceuticals for total equity value of $2.5 billion
Servier and Day One Biopharmaceuticals announce acquisition to expand Servier's rare oncology portfolio
Day One Biopharmaceuticals: 'Strong Buy,' Several 2026 Milestones In Play Plus OJEMDA Growth
Day One Biopharmaceuticals: Commercial Performance With Catalysts Ahead
Day One Biopharmaceuticals, Inc. (DAWN) Q4 2025 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue Estimates
Day One Reports Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Outlook and Revenue Guidance
Will Day One Biopharmaceuticals, Inc. (DAWN) Report Negative Earnings Next Week? What You Should Know
Day One To Report Fourth Quarter and Full-Year 2025 Financial Results Tuesday, February 24, 2026
Wall Street Analysts See a 101.08% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
Best Momentum Stocks to Buy for January 27th
New Strong Buy Stocks for January 27th
Wall Street Analysts Think Day One Biopharmaceuticals (DAWN) Could Surge 107.36%: Read This Before Placing a Bet
Day One Biopharmaceuticals (DAWN) Surges 26.7%: Is This an Indication of Further Gains?
Day One Biopharmaceuticals, Inc. (DAWN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Day One Announces Preliminary 2025 OJEMDA™ Net Product Revenue And Provides 2026 Net Product Revenue Guidance
Day One Completes Acquisition of Mersana Therapeutics
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Consensus Recommendation of “Moderate Buy” from Analysts
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Alexander & Baldwin, Inc. (NYSE - ALEX), United Security Bancshares (Nasdaq - UBFO), Udemy, Inc. (Nasdaq - UDMY), Mersana Therapeutics, Inc. (Nasdaq - MRSN)
Day One Pharmaceuticals: Stock Surges Ahead Of Promising 2026 - I'm Bullish
Day One Biopharmaceuticals Sees Unusually High Options Volume (NASDAQ:DAWN)
Day One to Present at the 44th Annual J.P. Morgan Healthcare Conference
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Receives Average Recommendation of “Moderate Buy” from Analysts
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
Day One to Participate in the Piper Sandler 37th Annual Healthcare Conference
Wall Street Analysts Believe Day One Biopharmaceuticals (DAWN) Could Rally 161.36%: Here's is How to Trade
Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout
Day One to Acquire Mersana Therapeutics to Advance Mission to Bring New Medicines to People of All Ages with Life-Threatening Diseases
Day One Announces New OJEMDA™ (tovorafenib) Data to be Presented in Oral Session at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
Day One Biopharmaceuticals, Inc. (DAWN) Q3 2025 Earnings Call Transcript
Day One Biopharmaceuticals, Inc. (DAWN) Reports Q3 Loss, Tops Revenue Estimates
Day One Reports Third Quarter 2025 Financial Results and Corporate Progress
Wall Street Analysts See a 234.66% Upside in Day One Biopharmaceuticals (DAWN): Can the Stock Really Move This High?
Day One to Report Third Quarter 2025 Financial Results Tuesday, November 4, 2025